Diabetes Patients' Breakthrough: Novo Nordisk's Ozempic® and Rybelsus® Launch Exclusively on JD Health

Recently, Novo Nordisk’s two blockbuster glucose-lowering drugs—Ozempic^®(Generic name: Semaglutide Injection) and Novoheal^®(Generic Name: Semaglutide Tablets) Exclusively Launched on JD Health. NovoThera^®Since its launch in China in 2021, it has been widely recognized by clinicians and patients for its superior glucose-lowering efficacy, cardiovascular and metabolic benefits, and the convenience of once-weekly dosing. This inaugural online sale via JD Health marks a new chapter in Novo Nordisk’s formal collaboration with online channels. And Novo Xin^®As the world’s first oral GLP-1RA, which was just fully launched in China in January 2025, its online debut on JD Health will provide a new medication option for more patients with type 2 diabetes.

JD Health will leverage its robust supply chain and healthcare service capabilities to comprehensively enhance the accessibility of these two medications, offering patients with diabetes new treatment options.

Ozempic^®(Semaglutide Injection), as a long-acting GLP-1 receptor agonist with a half-life of up to 7 days, requires only once-weekly administration to achieve potent glycemic control and precise target attainment. In its registration clinical trials in China, the rate of glycated hemoglobin (HbA1c) target achievement was as high as 86.1%, with an extremely low incidence of hypoglycemia. Furthermore, the SUSTAIN 6 study demonstrated that Ozempic^®Significantly reduces the risk of major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes, and markedly improves multiple parameters including body weight, blood pressure, and blood lipids, thereby delivering comprehensive cardiometabolic benefits to patients.

NovoXin^®(Semaglutide Tablets) Leveraging the innovative “SNAC absorption enhancer” technology, it has overcome the challenge of oral administration for biologic peptide drugs, enabling the convenience of once-daily oral dosing. The global Phase 3 clinical trial program, PIONEER, has demonstrated its significant glucose-lowering efficacy and multiple metabolic benefits, including weight reduction, blood pressure lowering, and lipid regulation. In patients with type 2 diabetes in China, NovoYi^®Post-treatment, the maximum reduction in HbA1c was 1.6%, with a target attainment rate of up to 92.3%. The greatest weight loss reached 3.4 kg, blood pressure decreased by as much as 4 mmHg, and fasting lipid profiles showed significant improvement.

JD Health will leverage its robust omnichannel supply chain and comprehensive scenario-based medical and healthcare service capabilities to support NovoThera^®He Nuohexin^®JD Health provides professional cold-chain logistics and dedicated team support to ensure that medications are safely delivered to patients under continuous temperature-controlled conditions without any breaks in the cold chain. In addition, JD Health will collaborate with Novo Nordisk to launch disease education and patient service initiatives, leveraging science popularization articles, expert videos, and other content to enhance public health literacy regarding metabolic diseases.

A JD Health representative stated, “This strategic partnership with Novo Nordisk represents a significant step for JD Health in enhancing drug accessibility. We aim to leverage our efforts to enable more patients to conveniently access these two innovative medicines and benefit from professional healthcare services.”

Doctors at JD Health Internet Hospital also specifically reminded that NovoTherapy^®He Nuohexin^®All are prescription drugs, which must be purchased with a prescription from a physician or other licensed healthcare professionals authorized to prescribe, and used rationally under the guidance of physicians, pharmacists, or other qualified healthcare professionals.